Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Penelope Gray

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Plos One|July 11, 2024
Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022Penelope Gray, Tiina Eriksson, Lovisa Skoglund, et al.
International Journal of Cancer|November 7, 2025
Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated womenMònica Ortega Llobet, Penelope Gray, Iacopo Baussano, et al.
NPJ Vaccines|August 13, 2024
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort studyPenelope Gray, Filipe Colaço Mariz, Carina Eklund, et al.
The Lancet. Infectious Diseases|June 3, 2021
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trialsFilipe Colaço Mariz, Penelope Gray, Noemi Bender, et al.
International Journal of Cancer|January 30, 2018
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)Penelope Gray, Johanna Palmroth, Tapio Luostarinen, et al.
Ebiomedicine|December 12, 2025
Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settingsJohannes M A Kusters, Nicole Brenner, Johannes A Bogaards, et al.
Frontiers in Cellular and Infection Microbiology|September 24, 2024
Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma <i>in situ</i>-population-based follow-up of two cluster-randomized trialsMatti Lehtinen, Penelope Gray, Tapio Luostarinen, et al.
International Journal of Cancer|May 27, 2024
Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesionsKarolina Louvanto, Lisanne Verhoef, Ville Pimenoff, et al.
International Journal of Cancer|November 22, 2019
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated womenKarolina Louvanto, Tiina Eriksson, Penelope Gray, et al.
BMJ Open|February 12, 2022
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trialMatti Lehtinen, Camilla Lagheden, Tapio Luostarinen, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Plos One|July 11, 2024
Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022Penelope Gray, Tiina Eriksson, Lovisa Skoglund, et al.
International Journal of Cancer|November 7, 2025
Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated womenMònica Ortega Llobet, Penelope Gray, Iacopo Baussano, et al.
NPJ Vaccines|August 13, 2024
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort studyPenelope Gray, Filipe Colaço Mariz, Carina Eklund, et al.
The Lancet. Infectious Diseases|June 3, 2021
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trialsFilipe Colaço Mariz, Penelope Gray, Noemi Bender, et al.
International Journal of Cancer|January 30, 2018
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)Penelope Gray, Johanna Palmroth, Tapio Luostarinen, et al.
Ebiomedicine|December 12, 2025
Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settingsJohannes M A Kusters, Nicole Brenner, Johannes A Bogaards, et al.
Frontiers in Cellular and Infection Microbiology|September 24, 2024
Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma <i>in situ</i>-population-based follow-up of two cluster-randomized trialsMatti Lehtinen, Penelope Gray, Tapio Luostarinen, et al.
International Journal of Cancer|May 27, 2024
Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesionsKarolina Louvanto, Lisanne Verhoef, Ville Pimenoff, et al.
International Journal of Cancer|November 22, 2019
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated womenKarolina Louvanto, Tiina Eriksson, Penelope Gray, et al.
BMJ Open|February 12, 2022
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trialMatti Lehtinen, Camilla Lagheden, Tapio Luostarinen, et al.
Pageof 2